"A weight-loss drug popular in Europe failed to slow heart disease by a key measure in obese patients with fat around the middle, and it significantly raised the risk of anxiety and depression, U.S. researchers said on Tuesday.More than 40 percent of patients who took rimonabant, sold as Acomplia in Europe, developed psychiatric problems, and one committed suicide, the researchers told an American College of Cardiology meeting in Chicago."
But, in spite of oops...
"However, they said patients who got rimonabant did show signs of improvement in a secondary measurement of coronary artery disease, suggesting the drug should be studied further."
They won't rest until they kill you.
That is if being fat doesn't do the trick first.
Posts
No comments:
Post a Comment